JPS6024764B2 - インドメタシンを含む局所薬 - Google Patents

インドメタシンを含む局所薬

Info

Publication number: JPS6024764B2
Authority: JP; Japan
Prior art keywords: polyethylene glycol; indomethacin; ether; molecular weight; topical
Prior art date: 1980-02-18
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

JP56021633A

Other languages

English (en)

Japanese (ja)

Other versions

JPS56135413A (en

Inventor

カ−ル・エルンスト・シユルテ

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

SORUFUON ARUTSUNAIMITSUTERU FUERUTORIIBUSU UNTO RIITSUENTSU GmbH

Original Assignee

SORUFUON ARUTSUNAIMITSUTERU FUERUTORIIBUSU UNTO RIITSUENTSU GmbH

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1980-02-18

Filing date

1981-02-18

Publication date

1985-06-14

1981-02-18 Application filed by SORUFUON ARUTSUNAIMITSUTERU FUERUTORIIBUSU UNTO RIITSUENTSU GmbH filed Critical SORUFUON ARUTSUNAIMITSUTERU FUERUTORIIBUSU UNTO RIITSUENTSU GmbH

1981-10-22 Publication of JPS56135413A publication Critical patent/JPS56135413A/ja

1985-06-14 Publication of JPS6024764B2 publication Critical patent/JPS6024764B2/ja

Status Expired legal-status Critical Current

Links

CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 title claims description 53
229960000905 indomethacin Drugs 0.000 title claims description 26
229940079593 drug Drugs 0.000 title claims description 14
239000003814 drug Substances 0.000 title claims description 14
230000000699 topical effect Effects 0.000 title claims description 9
229920001223 polyethylene glycol Polymers 0.000 claims description 34
239000002202 Polyethylene glycol Substances 0.000 claims description 31
239000000203 mixture Substances 0.000 claims description 19
229920001515 polyalkylene glycol Polymers 0.000 claims description 9
239000002674 ointment Substances 0.000 claims description 8
150000005215 alkyl ethers Chemical class 0.000 claims description 5
LTSWUFKUZPPYEG-UHFFFAOYSA-N 1-decoxydecane Chemical compound CCCCCCCCCCOCCCCCCCCCC LTSWUFKUZPPYEG-UHFFFAOYSA-N 0.000 claims description 4
230000009974 thixotropic effect Effects 0.000 claims 1
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 15
238000009472 formulation Methods 0.000 description 11
OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 10
125000004432 carbon atom Chemical group C* 0.000 description 9
125000000217 alkyl group Chemical group 0.000 description 8
229960001047 methyl salicylate Drugs 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
208000034656 Contusions Diseases 0.000 description 3
239000012049 topical pharmaceutical composition Substances 0.000 description 3
208000025978 Athletic injury Diseases 0.000 description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
239000013543 active substance Substances 0.000 description 2
230000000202 analgesic effect Effects 0.000 description 2
230000003110 anti-inflammatory effect Effects 0.000 description 2
230000001754 anti-pyretic effect Effects 0.000 description 2
239000002221 antipyretic Substances 0.000 description 2
VBICKXHEKHSIBG-UHFFFAOYSA-N beta-monoglyceryl stearate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
230000002757 inflammatory effect Effects 0.000 description 2
230000004936 stimulating effect Effects 0.000 description 2
238000003756 stirring Methods 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
201000005569 Gout Diseases 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
208000007107 Stomach Ulcer Diseases 0.000 description 1
125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
230000003444 anaesthetic effect Effects 0.000 description 1
230000036592 analgesia Effects 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
229940125716 antipyretic agent Drugs 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
238000004820 blood count Methods 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
239000002537 cosmetic Substances 0.000 description 1
239000006071 cream Substances 0.000 description 1
230000006378 damage Effects 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
230000000694 effects Effects 0.000 description 1
125000004185 ester group Chemical group 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
239000012467 final product Substances 0.000 description 1
210000001156 gastric mucosa Anatomy 0.000 description 1
201000005917 gastric ulcer Diseases 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
230000009965 odorless effect Effects 0.000 description 1
239000002304 perfume Substances 0.000 description 1
-1 polyethylene glycol Chemical compound 0.000 description 1
229920001451 polypropylene glycol Polymers 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
150000003902 salicylic acid esters Chemical class 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000007916 tablet composition Substances 0.000 description 1
238000005809 transesterification reaction Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pain & Pain Management (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Indole Compounds (AREA)

JP56021633A 1980-02-18 1981-02-18 インドメタシンを含む局所薬 Expired JPS6024764B2 (ja)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE3006024A DE3006024C2 (de)	1980-02-18	1980-02-18	Topisches, Indomethacin enthaltendes Arzneimittel in Salbenform
DE3006024.3		1980-02-18

Publications (2)

Publication Number	Publication Date
JPS56135413A JPS56135413A (en)	1981-10-22
JPS6024764B2 true JPS6024764B2 (ja)	1985-06-14

Family

ID=6094913

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP56021633A Expired JPS6024764B2 (ja)	1980-02-18	1981-02-18	インドメタシンを含む局所薬

Country Status (11)

Country	Link
JP (1)	JPS6024764B2 (es)
AT (1)	AT373148B (es)
BE (1)	BE887541A (es)
CH (1)	CH645541A5 (es)
DE (1)	DE3006024C2 (es)
ES (1)	ES8201826A1 (es)
FR (1)	FR2475897A1 (es)
GB (1)	GB2069334B (es)
IT (1)	IT1136564B (es)
NL (1)	NL8100503A (es)
SE (1)	SE447060B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5815940A (ja) *	1981-07-23	1983-01-29	Eisai Co Ltd	ポリプレニル系化合物およびその製造方法ならびにそれを含有する医薬
JPS59227818A (ja) *	1983-06-09	1984-12-21	Mitsubishi Chem Ind Ltd	ゲル状軟膏剤
CH643138A5 (de) *	1983-08-29	1984-05-30	Mepha Ag	Indomethacin enthaltende, gelartige salbe.
AU573321B2 (en) *	1984-03-14	1988-06-02	Jerome Corbiere	Process for solubilizing active principles and pharmaceuticalcompositions thus obtained
JPS60224638A (ja) *	1984-04-23	1985-11-09	Kao Corp	経皮吸収促進剤およびこれを含有する外用剤
JPH07112984B2 (ja) *	1989-04-28	1995-12-06	久光製薬株式会社	泡状エアゾール製剤

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3624197A (en) *	1969-09-04	1971-11-30	Philip Schain	Water-soluble tissue infiltrating and embedding compositions
BE756975A (fr) *	1970-06-09	1971-04-02	Merck & Co Inc	Suppositoires
US4011313A (en) *	1974-06-07	1977-03-08	Syntex (U.S.A.) Inc.	Medicament preparations
JPS5320417A (en) *	1976-08-10	1978-02-24	Yamanouchi Pharmaceut Co Ltd	New composition of preparation for rectal application
GB2023000B (en) *	1978-06-17	1982-10-13	Kowa Co	Antinflammatory analgesic gelled ointments

1980
- 1980-02-18 DE DE3006024A patent/DE3006024C2/de not_active Expired
1981
- 1981-01-29 SE SE8100623A patent/SE447060B/sv not_active IP Right Cessation
- 1981-01-29 GB GB8102674A patent/GB2069334B/en not_active Expired
- 1981-02-02 CH CH67181A patent/CH645541A5/de not_active IP Right Cessation
- 1981-02-03 NL NL8100503A patent/NL8100503A/nl not_active Application Discontinuation
- 1981-02-05 AT AT0051381A patent/AT373148B/de not_active IP Right Cessation
- 1981-02-17 FR FR8103119A patent/FR2475897A1/fr active Granted
- 1981-02-17 BE BE0/203809A patent/BE887541A/fr not_active IP Right Cessation
- 1981-02-18 JP JP56021633A patent/JPS6024764B2/ja not_active Expired
- 1981-02-18 ES ES500421A patent/ES8201826A1/es not_active Expired
- 1981-02-18 IT IT19824/81A patent/IT1136564B/it active

Also Published As

Publication number	Publication date
FR2475897A1 (fr)	1981-08-21
SE447060B (sv)	1986-10-27
FR2475897B1 (es)	1984-02-10
ATA51381A (de)	1982-06-15
DE3006024A1 (de)	1981-08-20
ES500421A0 (es)	1982-01-16
DE3006024C2 (de)	1983-08-04
NL8100503A (nl)	1981-09-16
IT1136564B (it)	1986-09-03
AT373148B (de)	1983-12-27
GB2069334B (en)	1983-10-19
SE8100623L (sv)	1981-08-19
ES8201826A1 (es)	1982-01-16
GB2069334A (en)	1981-08-26
IT8119824A0 (it)	1981-02-18
CH645541A5 (de)	1984-10-15
JPS56135413A (en)	1981-10-22
BE887541A (fr)	1981-06-15

Publication	Publication Date	Title
US5314915A (en)	1994-05-24	Bioadhesive pharmaceutical carrier
US5985860A (en)	1999-11-16	System for transdermal delivery of pain relieving substances
US5374661A (en)	1994-12-20	Composition and method for transdermal delivery of diclofenac
AU735815B2 (en)	2001-07-19	Composition for suppositories
JPWO2002024161A1 (ja)	2004-01-29	直腸下部滞留型坐剤
US3769427A (en)	1973-10-30	Pharmaceutical compositions and methods of using same
EP0186241A1 (en)	1986-07-02	Hydrocodone/ibuprofen pharmaceutical compositions and method
JPH09165344A (ja)	1997-06-24	膣用固形医薬品組成物
EP0066918A1 (en)	1982-12-15	Anti-inflammatory compositions exhibiting minimized gastric damage
US4310525A (en)	1982-01-12	Method of treatment of inflammation
KR900012892A (ko)	1990-09-03	항-염증성 아릴 화합물
RU2005122466A (ru)	2006-01-20	Фармацевтические композиции, включающие комбинацию кальцитриола и клобетазола пропионат
US4287174A (en)	1981-09-01	Anti-ulcer composition
GB2069334A (en)	1981-08-26	Topical medicine containing indomethacin
CN119499178A (zh)	2025-02-25	一种基于氟比洛芬的镇痛喷雾及制备方法
KR950703338A (ko)	1995-09-20	3-치환된 2-옥스인돌-1-카복스아미드 약학 조성물(3-substituted 2-oxindole-1-carboxamide pharmaceutical compositions)
JPH044300B2 (es)	1992-01-27
DE3580277D1 (de)	1990-11-29	Chemische verbindung mit antimykotischer, vernarbungsfoerdernder und entzuendungshemmender wirkung.
JP2679168B2 (ja)	1997-11-19	注入坐剤
Katona et al.	1988	Clinical experiences with the intramuscular injection of tiaprofenic acid in rheumatic diseases, with particular emphasis on time of onset and duration of the analgesic effect
US20050042241A1 (en)	2005-02-24	Dr. Bob's Arthritis Cream
GB2236250A (en)	1991-04-03	Ibuprofen solutions and topical compositions
JPH0276816A (ja)	1990-03-16	外用剤
KR890004345B1 (ko)	1989-10-31	알칸카복실산염의 제조방법
TW200528115A (en)	2005-09-01	External preparation for treatment of skin or mucous membrane injury due to virus infection